Astrazeneca Pharma Peer Comparison

NSE: ASTRAZEN | BSE: 506820

₹7,106.50

₹-29.50 (-0.41%)

As on 28-Aug-2026IST

Market cap

₹17,766 Cr

Revenue (TTM)

₹2,432 Cr

P/E Ratio

104.7

P/B Ratio

19.6

Div. Yield

0.5 %

Edit

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Market cap (₹ Cr)	17,766	21,501	19,125	18,253	17,685
Revenue (₹ Cr)	2,432	2,570	2,287	3,230	1,682
Net Profit (₹ Cr)	169.62	735.15	678.07	666.92	273.51
Net Margin (%)	6.90	26.88	28.10	20.60	16.19
RoE (%)	20.76	19.16	19.73	18.75	11.15
Price to Earnings	104.74	29.25	28.74	28.35	59.48
Price-To-Book	19.65	4.88	5.08	4.51	6.58

Income Statement (₹ Cr)

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Operating Revenue	2,275.58	2,519.65	1,937.47	2,893.64	1,538.87
Total Income	2,304.07	2,707.60	2,033.90	2,912.00	1,602.52
Total Expenditure	2,013.55	1,615.47	1,290.54	1,876.44	1,157.98
EBITDA	262.03	904.18	646.93	1,017.20	380.89
Depreciation	28.58	57.73	65.96	315.46	119.72
EBIT	233.45	846.45	580.97	701.74	261.17
Interest	4.49	9.57	0.61	231.29	58.79
Other Income	28.49	187.95	96.43	18.36	63.65
Exceptional Items	-5.25	-49.16	--	--	12.16
Profit before Tax	252.20	975.67	676.78	488.87	295.31
Provision for Tax	64.68	253.24	135.69	114.20	51.98
Profit after Tax	187.52	722.43	541.09	374.67	243.33

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Shareholder's Funds	872.79	4,202.90	2,850.49	2,854.36	2,591.20
Minority Interest	--	--	35.90	417.40	1.04
Non-Current Liabilities	394.49	19.19	13.24	2,100.97	249.46
Current Liabilities	1,109.50	627.48	305.99	1,489.55	848.06
Total Liabilities	2,414.58	4,921.88	3,207.85	6,862.28	3,705.61

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Non-Current Assets	509.16	1,046.35	1,071.67	5,531.13	2,578.95
Current Assets	1,859.88	3,803.22	2,133.95	1,331.15	1,109.77
Total Assets	2,414.58	4,921.88	3,207.85	6,862.28	3,705.61
Total Debt*	0.00	2.50	0.55	2,421.66	657.97
Net Current Assets	750.38	3,175.74	1,827.96	-158.40	261.71
Contingent Liabilities	121.23	370.49	0.64	64.29	160.01

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Cash From Operating Activities	-15.14	967.57	432.37	1,065.01	342.18
Cash Flow from Investing Activities	18.69	-561.67	-334.73	-79.97	-325.92
Cash from Financing Activities	-91.97	-798.31	-38.32	-881.32	13.62
Net Cash Inflow / Outflow	-88.42	-392.41	59.32	103.72	29.88

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
ROCE (%)	31.24	23.39	26.22	13.59	11.43
ROE (%)	23.02	17.16	21.72	13.81	9.82
ROA (%)	8.90	14.91	18.37	5.48	6.97
EBIT Margin (%)	12.77	43.34	38.37	35.79	28.89
Net Margin (%)	8.14	26.68	26.60	12.87	15.18
Cash Profit Margin (%)	9.47	29.72	31.33	23.22	23.59

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Revenue Growth (%)	32.59	10.45	14.37	44.02	19.62
EBIT Growth (%)	-1.38	19.68	20.21	48.22	29.72
Net Profit Growth (%)	62.02	-5.88	17.27	-5.65	210.81
EPS Growth (%)	62.02	-5.88	17.25	-10.39	210.80
Book Value Growth (%)	13.51	-0.34	23.77	10.19	9.67

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Price / Earnings	103.45	29.89	28.38	54.83	28.03
Price / Book Value	22.39	5.14	5.52	6.78	2.63
Dividend Yield (%)	0.46	1.59	0.30	0.52	0.17
EV/EBITDA	65.23	16.93	19.78	20.75	16.72
Market Cap (₹ Cr)	19,398.64	21,592.90	15,219.80	19,292.77	6,819.66

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Debt to Equity	0.00	0.00	0.00	0.85	0.25
Short term debt to equity ratio	--	0.00	0.00	0.14	0.16
Current Ratio	1.68	6.06	6.97	0.89	1.31
Quick Ratio	0.75	5.31	5.88	0.67	0.88
Interest Coverage	57.17	102.95	1,110.48	3.11	6.02

	Astrazeneca Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Shilpa Medicare
Debtors to sales (%)	9.39	7.22	32.65	15.85	33.72
Asset Turnover	1.08	0.54	0.66	0.43	0.44
Receivable days	31.88	26.06	110.70	54.07	113.81
Inventory Days	126.03	65.95	65.86	32.16	84.76
Payable days	163.79	81.01	105.88	140.91	101.94
Cash Conversion Cycle	-5.88	11.00	70.68	-54.68	96.62

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.